China-based biotech company BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) announced that it has signed a strategic agreement with Ontada, a subsidiary of McKesson Corporation, to accelerate the development and use of real-world evidence (RWE) in support of BeiGene’s oncology products in the US market. The financial details of the agreement were not disclosed.
Partnership Details
Ontada, a unit of the US medical distribution giant McKesson, is an oncology technology and insights business. It combines technologies used by The US Oncology Network and other community oncology providers with real-world data and research. Under the partnership with BeiGene, the aim is to optimize the use of RWE to communicate value across key stakeholders, including patients, providers, and payers. The partnership also seeks to develop timely education on emerging science and therapeutic differentiation. Additionally, it aims to collaborate to advance the use of RWE in healthcare and regulatory decision-making to increase timely and affordable patient access to BeiGene’s oncology therapies.
BeiGene’s Future Plans
BeiGene’s ex-China Senior Vice President of Global Medical Affairs, Dr. Christiane Langer, stated that the company “aims to bring 10 molecules per year to the clinic starting in 2023.” The strategic partnership with Ontada / McKesson “will leverage Ontada’s technology platform and deep understanding of the experiences of patients treated in community oncology clinics to help accelerate both the development of the BeiGene portfolio and expand access to treatment options.”-Fineline Info & Tech
